- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Cytophage Technologies Ltd: Cytophage calls first phage treatment a success | 3 | Stockwatch | ||
| Di | Cytophage Technologies Ltd.: VIDEO ENHANCED Cytophage Technologies Reports Positive Outcome from Innovative Bacteriophage Therapy in Patient with Antibiotic-Resistant Infection | 2 | TheNewswire | ||
| Di | Cytophage Technologies berichtet über positives Ergebnis der innovativen Bakteriophagen-Therapie bei einer Patientin mit Antibiotika-resistenter Infektion | 239 | IR-WORLD | Winnipeg, den 17. Dezember 2024 - Cytophage Technologies Ltd. ("Cytophage" oder "das Unternehmen") (TSXV: CYTO /
FWB: 70G) freut sich, das positive Ergebnis des ersten kanadischen Patienten bekannt... ► Artikel lesen | |
| 12.12. | Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba | 1 | The Deep Dive | ||
| 12.12. | Cytophage Technologies Ltd: Cytophage forms partnership with Orthopaedic Innovation | 3 | Stockwatch | ||
| 12.12. | Cytophage Technologies Ltd.: New Partnership Between Cytophage, Orthopedic Innovation Centre Targets Prosthetic Joint Infections Using Phage Therapy | 2 | TheNewswire | ||
| 12.12. | Cytophage Technologies: Neue Partnerschaft mit dem Orthopedic Innovation Centre im Hinblick auf die Phagentherapie zielt auf Gelenkprotheseninfektionen ab | 196 | IR-WORLD | Cytophage-CEO Dr. Steven Theriault (links) mit OIC-Präsident und CEO Trevor Gascoyne (rechts) bei der Unterzeichnungszeremonie.
WINNIPEG, den 12. Dezember 2024 - Cytophage... ► Artikel lesen | |
| 06.12. | Cytophage Technologies Ltd: Cytophage opens 20,000 square ft facility in Winnipeg | 1 | Stockwatch | ||
| CYTOPHAGE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.12. | Cytophage Technologies Ltd.: Cytophage Celebrates Opening of State-of-the-Art Phage Production Facility in Winnipeg | 1 | TheNewswire | ||
| 28.11. | Cytophage Technologies reports Q3 results | 3 | Seeking Alpha | ||
| 28.11. | Cytophage Technologies Ltd.: Cytophage Reports Q3 2024 Financials and Business Update | 1 | TheNewswire | ||
| 16.11. | McDonald's E.coli Crisis: This Canadian Biotech May Have The Solution | Cytophage with Steven Theriault | 3 | The Deep Dive | ||
| 11.11. | Cytophage Technologies Ltd: Cytophage Technologies talks R&D work for AviPhage | 1 | Stockwatch | ||
| 11.11. | Cytophage Technologies Ltd.: Cytophage Highlights Existing Phage Solutions to Recent Harmful Bacteria Outbreaks in Food Systems | 1 | TheNewswire | ||
| 05.11. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 05.11.2024 | 533 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.11.2024
Aktien
1 CA13740E1079 Cancambria Energy Corp.
2... ► Artikel lesen | |
| 04.10. | Cytophage Technologies Ltd.: Cytophage CEO to Discuss Reshaping Healthcare Through Phage Therapies During 2024 Canada SynBio Conference | 6 | TheNewswire | ||
| 29.08. | Cytophage Technologies Ltd: Cytophage's June 30 cash at $3.65-million | 1 | Stockwatch | ||
| 28.08. | Cytophage Technologies reports Q2 results | 1 | Seeking Alpha | ||
| 28.08. | Cytophage Technologies Ltd.: Cytophage Reports Q2 Financials including Business Update for First Half of 2024 | 1 | TheNewswire | ||
| 15.08. | Cytophage Technologies Ltd: Cytophage rolls out lyophilized tablets for poultry | 1 | Stockwatch |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,10 | -0,37 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,400 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| PRAXIS PRECISION MEDICINES | 76,52 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | 0,00 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | 0,00 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | 0,00 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| TEMPUS AI | 35,500 | 0,00 % | Tempus AI's (TEM) AI-Powered Healthcare Revolution: What's Next? | ||
| HUMACYTE | 4,635 | 0,00 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| QIAGEN | 43,300 | +0,93 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| JANUX THERAPEUTICS | 56,70 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | 0,00 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | 0,00 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| EVOTEC | 8,335 | -0,83 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,035 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
CYTOPHAGE TECHNOLOGIES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,187 Euro und damit -6,50 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOPHAGE TECHNOLOGIES LTD finden Sie auf Wallstreet Online.
